The ability of ATRA to inhibit proliferation in RA FLSs through autophagy and apoptosis underscores its potential as a supplementary therapeutic agent alongside MTX for RA, particularly when compared to the limited impact of MTX on these processes. This combined strategy holds promise for enhancing therapeutic outcomes and warrants further investigation in the management of RA.
Keyphrases
- rheumatoid arthritis
- endoplasmic reticulum stress
- disease activity
- cell death
- signaling pathway
- oxidative stress
- ankylosing spondylitis
- interstitial lung disease
- cell cycle arrest
- systemic lupus erythematosus
- cell proliferation
- high dose
- big data
- type diabetes
- risk assessment
- metabolic syndrome
- pi k akt
- climate change
- systemic sclerosis
- skeletal muscle
- deep learning
- weight loss